High Dose Chemotherapy Followed By PBSC Rescue for HD
Not Applicable
Completed
- Conditions
- Hodgkin Disease
- Registration Number
- NCT00186251
- Lead Sponsor
- Stanford University
- Brief Summary
To evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation in the treatment of Hodgkin's Disease.
- Detailed Description
Use of High Dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
- adequate organ function
- recurrent HD
Exclusion Criteria
- CNS disease
- no prior malignancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Overall survival FFS Response rates
- Secondary Outcome Measures
Name Time Method Toxicity of high dose chemotherapy
Trial Locations
- Locations (1)
Stanford University School of Medicine
🇺🇸Stanford, California, United States
Stanford University School of Medicine🇺🇸Stanford, California, United States